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enough is known about cardiac remodeling in PPCM. The 
importance of inflammation has been highlighted in animal 
models and in patients.(6,12,13) Cardiac fibrosis has been 
demonstrated in PPCM animal models, but has not yet been 
explored in patients.(4)
PPCM is a disease which progresses quickly to cardiac 
dysfunction and failure. Its diagnosis is based on exclusion and 
still remains difficult. PPCM patients present with frequent 
symptoms of pregnancy, such as dyspnea, fatigue and exercise 
incapacity which may obscure early signs of heart failure.(14)
One important sign in PPCM is an elevated heart rate (HR). 
The maternal HR is elevated in normal pregnancy to efficiently 
eliminate metabolic waste and to cope with the oxygen demand 
of both the mother and the rapidly developing foetus, but 
recovers 1 - 2 months after delivery.(15,16) Interestingly, this is not 
the case with PPCM patients as they continue to display an 
elevated HR 6 months after delivery which represents 6 times 
the duration of normal recovery (Figure 1). 
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ABSTRACT
Peripartum Cardiomyopathy (PPCM) is a maternal condition 
which manifests with symptoms of heart failure between the 
last month of pregnancy and 5 months postpartum.(1) It is an 
important health concern in the sub-Saharan region of Africa, 
with approximately 1 in 1 000 pregnant women affected by the 
condition in South Africa.(2) 
The time course and evolution of the disease is not well 
understood and the large variability between patients’ 
phenotypes may explain that. Indeed, one main patho-
physiological feature of PPCM is left ventricular systolic 
dysfunction (ejection fraction <45%). However, only a sub-
group of patients presents with left ventricular dilatation.(1) The 
precise mechanism leading to left ventricular dysfunction in 
human PPCM remains undefined. Several experimental and 
clinical studies lend support to the hypothesis that increased 
oxidative stress, as evidenced by increased circulating levels of 
pro-oxidative factors in PPCM patients, may play an important 
role in the initiation of the disease.(3,4) Oxidative stress, together 
with excess anti-angiogenic signaling, leads to vessels rarefica-
tion.(5,6) As for diabetic cardiomyopathy,(7) microvascular insuf-
ficiency has been suggested to be the driver of PPCM 
pathogenesis. Endothelial dysfunction and an imbalance of 
angiogenesis seem to promote metabolic shortage in the heart 
leading to cardiomyocytes apoptosis,(8,9) further leading to heart 
failure in PPCM.(10,11) 
The rapid cardiac decompensation observed in PPCM patients 
may be explained by maladaptive remodeling. However, not 
During pregnancy, heart rate (HR) is physiologically 
elevated but recovery occurs within 4 weeks of delivery. 
Peripartum cardiomyopathy (PPCM) is an acute con-
dition which manifests with symptoms of heart failure 
late during pregnancy, or within 6 months of delivery. 
One of its main symptoms is elevated HR. Current 
standard therapy for PPCM makes use of diuretics, 
ACE inhibitors and beta-blockers. This approach does 
not satisfactorily improve HR in patients, even after 
6 months of treatment. Strong evidence from both 
experimental and clinical studies suggests that modu-
lation of the sino-atrial node with drugs such as 
ivabradine may benefi t patients suffering from PPCM. 
The activity of ivabradine is likely two-fold – direct with 
regards to heart rate and indirect with long-term 
structural changes affecting the heart itself, as well as 
the vascular and endogenous physiological systems. 
Large clinical trials are needed to validate this con-
cept and further exploration of this hypothesis in an 
established rodent model of PPCM is required to 
investigate the outcome on both HR and its effects on 














Data collected from 27 patients with PPCM at Groote Schuur 
hospital showed a mean heart rate of 101 ± 3 beats per minute 
(BPM) at baseline and 83 ± 2 BPM at 6 months (these data 
confirm a previous publication by Libhaber, et al.(17)). Few 
patients recover to a healthy heart rate of 75 BPM after 
6 months on current standard therapy (see Figure 2). Only 
4 patients had recovered to below 75 BPM, this value 
corresponding with the upper limit of a healthy HR, as per the 
ESC guidelines.(18)
An elevated HR, at baseline, might be associated with poor 
outcomes in these patients (Table I). This is in accordance with 
our recent collaborative study which demonstrates that PPCM 
patients with elevated HR and low systolic blood pressure had 
the highest mortality.(17)
Management of acute heart failure in PPCM follows the same 
principles as those applying to acute heart failure arising from 
any other cause.(1,18) The drugs most commonly used include 
diuretics, angiotensin-converting enzyme inhibitors (ACEi) and 
beta-blockers.
The impact of diuretics on heart failure is mainly symptomatic, 
via reduced pre-load. ACEi treatment leads to better 
oxygenation of tissues, lowers blood pressure, and reduces 
water retention, improving breathing ability and contractility of 
the heart as secondary outcomes. Beta blockers competitively 
inhibit the beta adrenergic receptors, improving existing 
contractility and HR independently of the activation of the 
sympathetic nervous system. These current treatment strate-
gies have shown to be effective in improving the symptoms 
of fluid overload and cardiac function. However, our recent 
observations demonstrated their insufficiency to improve HR 
in PPCM patients after 6 months of treatment (Figure 2), 
supporting the idea that targeting HR directly in PPCM may be 
beneficial. 
Experimental studies suggest that reducing HR with an inhibitor 
of the sino-atrial node, a cluster of cells which serves as the 
pacemaker of the heart, may be of benefit in the recovery of 
heart failure.(19)
One such drug which fulfils this purpose is ivabradine, a selec-
tive inhibitor of the hyperpolarisation activated cyclic-
nucleotide-gated funny current (If) which regulates the pace-
maker activity of the sino-atrial node. As such, ivabradine results 
in HR reduction and targeting HR directly in PPCM may be 
beneficial. It has been investigated in the SHIFT trial for the 
treatment of chronic heart failure where it was shown to 
improve critical outcomes as a complement to other recom-
mended therapy simply by its action on heart rate.(19) In 
accordance to ESC guidelines, the use of ivabradine may be of 
interest in PPCM patients as a complementary therapy with an 
evidence-based dose of beta-blocker (or maximum tolerated 
dose). Ivabradine may also be used as an alternative to β-blocker 
in patients with low blood pressure who are intolerant to 
β-blockers, as it has no ionotropic effects and thus does not 
alter the strength of contraction of the heart muscle as 
β-blockers would.(1,18)




















Recently HR has been investigated retrospectively as a target to 
improve the overall outcome in acute heart failure in PPCM 
patients.(20) Patients with acute PPCM were randomly treated 
with ivabradine early after diagnosis to evaluate the validity of 
the hypothesis that the sino-atrial node may be a viable target 
to improve the outcome of heart failure by means of improving 
the HR. All patients received guideline-recommended heart 
failure treatment, including maximally achievable beta-blockade. 
Despite the small sample size, a significant HR reduction was 
observed (108 ± 14 BPM at baseline vs. 61 ± 10 BPM at 
6-months follow-up visit, p<0.0001) and this decease correlated 
with an improvement of cardiac function (25 ± 9% at baseline 
vs. 45 ± 8% at 6 months follow-up visit, p<0.0001). This 
preliminary study is a step forward towards improving the 
management and the outcome of PPCM patients and it further 
encourages investigations on targeting HR as a potential 
treatment for these patients. 
In addition to its activity on heart rate via the sino-atrial node, 
ivabradine appears to have secondary effects on cardiac and 
related systems. In a rodent model, ivabradine reduced ven-
tricular expression of angiotensin-converting enzyme and 
angiotensin II type 1 receptor (AT1) when used in a model of 
chronic heart failure following a severe ischaemic event.(21,22) 
It prevented worsening of left ventricular dysfunction, and 
improved systemic level endothelial function – perhaps as an 
indirect effect to HR reduction.(23) Long-term treatment with 
ivabradine appeared to prevent the deposition of cardiac 
collagen involved in fibrotic remodeling. These changes in 
remodeling were associated with cardiac downregulation of the 
renin-angiotensin-aldosterone system transcripts and occur 
simultaneously with potent anti-oxidant effects regulated by 
the reduction of vascular NADPH oxidase activity.(24) It 
improved endothelial function and modulated the migration of 
immune cells – lymphocytes in particular, which play a key role 
in inflammation – this may be the path by which ivabradine 
attenuates cardiac remodeling.(25)
In conclusion, evidence from both experimental and clinical 
studies suggests that modulation of the sino-atrial node with 
drugs such as ivabradine may benefit patients suffering from 
PPCM. The activity of ivabradine is likely two-fold – direct with 
regards to heart rate and indirect with long-term structural 
changes affecting the heart itself, as well as the vascular and 
endogenous physiological systems. Large clinical trials are 
needed to validate this concept and further exploration of this 
hypothesis in an established rodent model of PPCM is required 
to investigate the outcome on both HR and its effects on other 
observable systems affected by PPCM. 
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RESEARCH HYPOTHESIS
TABLE I: Cardiac parameters observed in PPCM patients at base-
line and after 6 months of current recommended therapy indicates 
that patients are initially in heart failure (indicated by the left 
ventricular ejection fraction (EF) <45%), and show some improve-
ment with time. There is also a shift from higher to lower New York 
heart Association (NYHA) class at baseline compared to 6 months, 
which reflects this improvement (personal unpublished data).
   Baseline 6 months PP
NYHA class 1 n 0 11
 Mean HR (BPM) - 77 ± 2
 EF (%) - 50 ± 2
NYHA class 2 n 11 12
 Mean HR (BPM) 97 ± 4 84 ± 4
 EF (%) 33 ± 2 37 ± 3
NYHA class 3 n 14 2
 Mean HR (BPM) 104 ± 4 106 ± 6
 EF (%) 29 ± 3 36 ± 4
NYHA class 4 n 4 0
 Mean HR (BPM) 107 ± 8 -
 EF (%) 23 ± 7 -
FIGURE 2: Change in heart rate of individual PPCM patients 
after 6 months on current, recommended therapy. A normal 
resting HR should be <75 BPM (indicated by the red, dotted 
line). After 6 months of therapy, only 4 of the 27 patients 
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